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Introduction: Invasive mold disease is an important complication of patients with hema-
tologic malignancies, and is associated with high mortality. A diagnostic-driven approach
has  been an alternative to the classical empiric antifungal therapy. In the present study
we  tested an algorithm that incorporated risk stratiﬁcation using the D-index, serial serum
galactomannan and computed tomographic-scan to guide the decision to start antifungal
therapy in neutropenic patients.
Patients and methods: Between May 2010 and August 2012, patients with acute leukemia
in  induction remission were prospectively monitored from day 1 of chemotherapy until
discharge or death with the D-index and galactomannan. Patients were stratiﬁed in low,
intermediate and high risk according to the D-index and an extensive workup for invasive
mold disease was performed in case of positive galactomannan (≥0.5), persistent fever, or
the  appearance of clinical manifestations suggestive of invasive mold disease.
Results: Among 29 patients, 6 (21%), 11 (38%), and 12 (41%) were classiﬁed as high, interme-
diate, and low risk, respectively. Workup for invasive mold disease was undertaken in 67%,
73%  and 58% (p = 0.77) of patients in each risk category, respectively, and antifungal therapy
was  given to 67%, 54.5%, and 17% (p = 0.07). Proven or probable invasive mold disease was
diagnosed in 67%, 45.5%, and in none (p = 0.007) of high, intermediate, and low risk patients,
respectively. All patients survived.
Conclusion: A risk stratiﬁcation using D-index was a useful instrument to be incorporated in
invasive mold disease diagnostic approach, resulting in a more comprehensive antifungaltreatment strategy, and to guide an earlier start of treatment in afebrile patients under veryhigh  risk.
© 2016 Elsevier Ed
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ntroduction
nvasive mold disease (IMD) is an important complication
f patients with hematologic malignancies, and is associ-
ted with high mortality.1,2 Strategies to reduce the incidence
nd morbidity associated with IMD  include the use of anti-
ungal prophylaxis and empiric antifungal therapy.3,4 The
atter is considered standard of care in patients with per-
istent or recurrent fever and neutropenia, but since fever
s a non-speciﬁc manifestation and may have other etiolo-
ies (including uncontrolled occult bacterial infection, viral
nfection and drug fever),4 a signiﬁcant number of patients
eceive antifungal therapy unnecessarily. A diagnostic-driven
pproach has been studied as an alternative to the empiric
herapy. In this strategy, other parameters such as serial
erum Aspergillus galactomannan antigen (s-GMI) and com-
uted tomography (CT) of the chest and sinuses are used to
rigger the initiation of antifungal therapy.5–7 A major risk
actor for IMD  in hematologic patients is severe (<100/mm3)
eutropenia lasting >10–15 days,8–10 and clinicians rely on a
ertain duration of neutropenia above which an IMD is sus-
ected. A major limitation of this strategy is the lack of a
arameter that measures both the intensity and the duration
f neutropenia. We  developed an index (D-index) that com-
ines the intensity and duration of neutropenia, calculating
he area over the neutrophil curve. The index was tested ret-
ospectively in patients with acute myeloid leukemia (AML),
nd showed a good discriminatory performance in identify-
ng patients with IMD. A cut-off was derived, and showed
ood sensitivity, speciﬁcity, and a very high negative predic-
ive value (97–99%).11 The high negative predictive value of
his index is very similar to that obtained with s-GMI and
,3--d-glucan (BDG) in febrile neutropenic patients.12,13
In the present study we  tested an algorithm that incor-
orated the D-index, serial s-GMI and chest, and sinuses CT
n high-risk neutropenic patients. We aimed to deﬁne a risk
tratiﬁcation parameter to guide a comprehensive diagnostic
pproach, helping the decision to start antifungal therapy in
igh-risk neutropenic patients.
atients  and  methods
he study was conducted at the Hospital Universitário
lementino Fraga Filho, Federal University of Rio de Janeiro,
razil, a tertiary care hospital with ∼400 beds, including
 hematology and hematopoietic cell transplant (HCT) unit
ith eight single-bed rooms with high efﬁciency particulate
ir (HEPA) ﬁlter and positive pressure, and ﬁve double-bed
ooms without HEPA ﬁlter. The research was conducted in
ccordance with the Declaration of Helsinki and national
nd institutional standards. The institution’s Ethical Commit-
ee (“Comitê de Ética em Pesquisa do Hospital Universitário
lementino Fraga Filho”) approved the study (171/09). The
tudy was registered in ClinicalTrials.gov (NCT00982540).Between May 2010 and August 2012, all adult patients
age ≥18 years) with AML, acute lymphoid leukemia (ALL)
r myelodysplasia (MDS) undergoing induction remission
hemotherapy who signed an informed consent were included6;2 0(4):354–359 355
in the study. We excluded patients with a past history of or
an active IMD.  Patients were treated in rooms with HEPA ﬁl-
ters and received standard care for neutropenia, consisting of
antibacterial (ciproﬂoxacin) and antifungal prophylaxis (usu-
ally ﬂuconazole). In case of fever (>38 ◦C), blood cultures were
obtained and empiric antibiotic therapy with a -lactam was
started. Blood cultures were repeated in case of persistent or
recurrent fever, or as clinically indicated. Modiﬁcations in the
empirical antibiotic regimen were performed according to the
results of cultures and the clinical course of the patient.
Patients were monitored from day 1 of chemotherapy
until discharge or death with the D-index and s-GMI per-
formed three times per week (Platelia Aspergillus Ag Kit,
Bio-Rad, Marnes-la-Coquette, France). The D-index was cal-
culated using the results of absolute neutrophil counts (ANC)
performed three times per week, as previously described.11
Brieﬂy, the calculation of the D-index is based on a graph plot-
ting the ANC during the course of neutropenia, and is the area
over the neutrophil curve. Clinically it represents the deﬁcit of
neutrophils during the episode.
A workup for IMD (chest and sinus CT scan) was trig-
gered in the following situations: persistent (after six days of
antibiotics) or recurrent fever, clinical manifestations of IMD
(sinuses, pneumonia, skin nodules), or positive s-GMI (≥0.5).
Other tests, including bronchoalveolar lavage and biopsy of
skin lesions were performed if clinically indicated. The IMDs
were classiﬁed as proven, probable, or possible, as previously
deﬁned.14,15
Assuming the cut-off value of 5800 from the original
publication11 (negative predictive value of 97%) and 3000 (no
documentation of IMD below this value in the retrospec-
tive study), we stratiﬁed patients in three risk categories
based on the cumulative D-index: low (<3000), intermediate
(3000–5800), and high (>5800) (Table 1). Patients stratiﬁed as
high risk and either one positive s-GMI, any image  on CT scan
or any clinical signs or symptom suspicious of an IMD  received
systemic antifungal therapy (preferably caspofungin, at the
dose of 70 mg  on day 1 and 50 mg  on subsequent days, intra-
venously). Patients in the low risk group received systemic
antifungal therapy only in the presence of typical image  of IMD
on CT scan (well-circumscribed pulmonary inﬁltrates, air cres-
cent or cavitary lesions) plus two consecutive positive s-GMI,
or upon documentation of proven IMD.14 Patients in the inter-
mediate risk group received systemic antifungal therapy in the
presence of at least two consecutive positive s-GMI tests plus
any image  in CT scan, one positive s-GMI in the presence of
typical images (well-circumscribed inﬁltrates, air crescent or
cavity) or upon documentation of proven IMD.  In case of start
of antifungal treatment, the duration of therapy was deﬁned
by the attending physician on a case by case basis. Of note,
since D-index is a dynamic parameter, patients formerly in
the low or intermediate risk were classiﬁed as high risk group
once the cumulative D-index was >5800.
The outcomes of each initial risk group (low, moderate,
and high) were compared regarding the incidence of proved
and probable IMD, receipt of systemic antifungal therapy and
death. Fever was deﬁned as an axillary temperature ≥38 ◦C.
All data were collected in a case report form and analyzed
in the HUCFF. Descriptive data were expressed in percent-
ages and medians, with ranges. Dichotomous variables were
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Table 1 – Risk stratiﬁcation and criteria to initiate antifungal therapy.
Risk group D-index Criteria to initiate antifungal therapya
Low <3000 - Typical image of IMD on CT scan + 2 consecutive positive s-GMI
- Documentation of proven IMD
Intermediate 3000–5800 - 2 consecutive positive s-GMI + any image in CT scan
- 1 positive s-GMI + typical images in CT scan
- Documentation of proven IMD
High >5800 - 1 positive s-GMI
- Any image on CT scan
- Any clinical signs or symptom suspicious of an IMD
 galactomannan.
Table 2 – Characteristics of 29 episodes of induction
remission chemotherapy.
Characteristics Number
Age, in years median (range) 37 (19–72)
Underlying disease, n (%)a
Acute myeloid leukemia 16 (55.2)
Acute lymphoid leukemia 11 (37.9)
Myelodysplasia 2 (6.9)
Treatment phase, n (%)
First induction 19 (65.5)
Relapse 10 (34.5)
Antifungal prophylaxis, n (%) 29 (100)
Fluconazole 25 (86.2)
Voriconazole 1 (3.4)
Posaconazole 1 (3.4)
Blind study drugb 2 (6.9)
Antibacterial prophylaxis, n (%) 29 (100)
Febrile neutropenia, n (%) 27 (93.1)
Empiric antibiotic therapy, n (%)
Cefepime 20/27 (74.1)
Carbapenem 4/27 (14.8)
Piperacillin-tazobactam 3/27 (11.1)
Classiﬁcation of the febrile episode, n (%)
Fever of unknown origin 7/27 (25.9)
Bacteremiac 8/27 (29.6)
Clinically documented 4/27 (14.9)
Microbiologically documented without
bacteremia
8/27 (29.6)
Duration (days) of neutropenia, median (range) 14 (5–35)
Total D-indexd, median (range) 4763 (706–11,980)
a Chemotherapy regimen – AML: “7 + 3” cytarabine + daunorubicin
(8), “Flag-dauno” ﬂudarabine, cytarabine, ﬁlgastrim and daunoru-
bicin (4), cytarabine, daunorubicin and etoposide (2), decitabine
(1); ALL: “Hyper-C-VAD” cyclophosphamide, vincristine, doxoru-
bicin, dexamethasone, cytarabine and methotrexate (8) FLAG-
dauno (3); MDS: FLAG-dauno (1), 7 + 3 (1).
b Liposomal amphotericin B vs. placebo.
c Agents: coagulase-negative staphylococci (2), Staphylococcus
aureus (1), viridans Streptococcus (1), Escherichia coli (2), Pseudomonas
aeruginosa (1) and Enterobacter cloacae (1).IMD, invasive mold disease; CT, computed tomography; s-GMI, serum
a Any of these criteria.
compared using Chi-square or two-tailed Fisher’s exact test. A
p-value <0.05 was considered statistically signiﬁcant. Statisti-
cal analyses were performed using SPSS for Windows software
(version 15.0.1, SPSS, Inc., USA).
Results
Patients
During the study period a total of 32 episodes of induc-
tion remission were assessed for eligibility. Three of these
had a previous documentation of IMD,  and were excluded.
A total of 29 episodes of induction remission in 24 patients
(21 males, 87.5%) were included. As shown in Table 2, AML
accounted for the majority of episodes (16, 55.2%). All but
four patients received ﬂuconazole prophylaxis. Two patients
received anti-mold azole agents (voriconazole and posacona-
zole, 1 each) and two patients received a blind study drug
(liposomal amphotericin B or placebo). All patients survived
the episode of neutropenia and were discharged.
Invasive  mold  diseases
During the study, proven or probable IMD  was diagnosed in
nine episodes (31%): seven cases of invasive aspergillosis and
two of invasive fusariosis. In one episode a diagnosis of possi-
ble invasive aspergillosis was made.
Risk  stratiﬁcation  and  work-up  results
Two patients did not develop fever during the episode of neu-
tropenia; one was classiﬁed as low-risk as per the ﬁnal D-index
value, and one as high-risk. Among the 27 episodes with fever,
eight had no criteria to start an IMD  workup, and no antifun-
gal therapy was given: four were classiﬁed as low-risk, three
were in the intermediate risk, and one was in the high-risk. A
workup for IMD  was performed in the remaining 19 episodes;
antifungal therapy was given in 12 (41.3% of the 29 episodes).
Table 3 details the indications of workup for IMD,  risk stratiﬁ-
cation at the time of workup and antifungal therapy in these
19 episodes. Seven episodes were classiﬁed as low risk at the
moment of workup. While antifungal therapy was given in
two, no IMD  was diagnosed. Among eight episodes classiﬁed
as intermediate risk, six received antifungal therapy; proven
or probable IMD  was diagnosed in ﬁve and possible IMD in one.d D-index value from the start to the end of neutropenia.
Of note, fever was not present at the time of workup in one of
these episodes. The remaining four episodes were classiﬁed as
high-risk. All received antifungal therapy and had a diagnosis
of IMD (all probable invasive aspergillosis).
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Table 3 – Workup for invasive mold disease, risk stratiﬁcation and antifungal therapy in these 19 episodes of febrile
neutropenia.
Patient
number
D-index at
workup/risk group
Day of febrile
neutropeniaa
Indication for
workup
Antifungal
therapy
Final
diagnosis
D-index at the
end of the
episode
1 1766/Low 3 Fever, sinusitis Voriconazole No IMD 3928
2 2812/Low 4 Afebrile, 1 positive
s-GM, negative CT
None No IMD 3608
3 831/Low 5 Fever, typhlitis, 1
positive s-GMI
Caspofungin No IMD 3618
4 1766/Low 7 Fever, negative s-GM
and CT
None No IMD 3098
5 2382/Low 7 Fever, negative s-GM
and CT
None No IMD 2382
6 2118/Low 10 Fever, negative s-GM
and CT
None No IMD 5503
7 2682/Low 10 Fever, negative s-GM
and CT
None No IMD 4436
8 3089/Intermediate 4 Fever, 2 positive
s-GMI, non-speciﬁc
lung inﬁltrates on CT
Caspofungin Probable
aspergillosis
6268
9 3055/Intermediate 6 Fever, positive blood
culture and skin
lesions
Voriconazole +
L-AMB
Proven
fusariosis
6539
10 3295/Intermediate 7 Fever, negative s-GM
and CT
None No IMD 6528
11 3957/Intermediate 7 Fever, 2 positive
s-GMI, nodules and
consolidation on CT
Caspofungin
(voriconazole
added 7 days
later)
Probable
aspergillosis
6342
12 4762/Intermediate 9 Afebrile, skin
nodules
Voriconazole +
L-AMB
Proven
fusariosis
5196
13 4453/Intermediate 10 Fever, negative s-GM None No IMD 5959
14 4763/Intermediate 10 Fever, nodules with
halo sign on CT
Voriconazole Possible IMD 4763
15 5676/Intermediate 11 Fever, 1 positive
s-GMI, nodules on
CT
Voriconazole Probable
aspergillosis
6135
16 6158/High 6 Fever, 1 positive
s-GMI, nodules on
CT
Voriconazole Probable
aspergillosis
7230
17 6028/High 8 Afebrile, 1 positive
s-GMI, nodules with
halo sign on CT
Voriconazole +
caspofungin
Probable
aspergillosis
11,965
18 6211/High 12 Fever, 2 positive
s-GMI, nodules on
CT
Voriconazole +
caspofungin
Probable
aspergillosis
6613
19 7316/High 16 Fever, 2 positive
s-GMI, nodules on
CT
Voriconazole Probable
aspergillosis
11,581
IMD, invasive mold disease; s-GMI, serum Aspergillus galactomannan antigen; CT, computed tomography; L-AMB, lipid amphotericin B.
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Overall, considering febrile and afebrile patients, workup
or IMD  was necessary in 4 of 6 (66.7%) episodes classiﬁed as
igh-risk, 8 of 11 (72.7%) classiﬁed as intermediate risk, and 7
f 12 (58.3%) classiﬁed as low risk (p = 0.77). Antifungal therapy
as given to 4 of 6 (66.7%) episodes classiﬁed as high-risk, 6 of
1 (54.5%) classiﬁed as intermediate risk, and 2 of 12 (16.7%)
lassiﬁed as low-risk group (p = 0.07). Finally, proven or proba-
le IMD  was diagnosed in 4 of 6 (66.7%) episodes classiﬁed as
igh risk, 5 of 11 (45.5%) classiﬁed as intermediate risk, and in
one of the 12 episodes classiﬁed as low risk (p = 0.007).se.
A total of 299 s-GMI tests were performed, with a median
of 10 tests per episode (range 2–27). Of those, 51 tests (17.0%)
were positive in 20 episodes (68.9% of the episodes). The
test was considered false positive in 11 of the 20 episodes
based on clinical judgment. In seven of these 11 episodes
the patient was classiﬁed as low risk at the time of workup
(or at the end of the episode if workup was not under-
taken); the other four episodes were classiﬁed as intermediate
or high risk (3 and 1, respectively). In these four episodes,
only one s-GMI test was positive among 8, 9, 11, and 16
i s . 2 0358  b r a z j i n f e c t d 
tests performed per episode, respectively. In the low-risk
group, all seven positive s-GMI tests were false positive,
compared to three out of eight (37.5%) in the intermediate
risk group and one out of ﬁve (20%) in the high risk group
(p = 0.01).
Discussion
In this study we  showed that a dynamic assessment of the risk
of IMD  using the D-index may be of help to decide whether
antifungal therapy should be given to neutropenic patients.
Using this strategy that incorporated the D-index and serial
s-GMI assessment we  were able to avoid the initiation of anti-
fungal therapy based on just the presence of fever, and to start
an antifungal agent in afebrile patients, or earlier than day
7 of empiric antibiotic therapy in patients at high risk who
presented an indirect sign of IMD.
Empiric antifungal therapy consists in the initiation of
a systemic antifungal agent in neutropenic patients who
persist febrile on day 4–7 of antibiotic therapy or who
present recurrence of fever.16 Although its basis lacks solid
evidence,17,18 it became standard of care and is still endorsed
by guidelines.19,20 However, since the empiric therapy strategy
uses a non-speciﬁc parameter (fever) to trigger the initia-
tion of antifungal therapy, many  patients receive antifungal
therapy unnecessarily. In contrast with the empiric strat-
egy, a diagnostic-driven (or pre-emptive) approach takes into
account other parameters (such as positive s-GMI, PCR, images
and others) to initiate antifungal therapy. One randomized and
some non-randomized studies showed that the diagnostic-
driven approach can replace the empiric strategy provided
that the center is able to provide these tools in a timely
fashion.5–7,19–22
In the present study we  tested an algorithm for the deci-
sion to start antifungal therapy that incorporates the D-index.
This tool is inexpensive and easy to calculate. Conceptually
the D-index measures the deﬁcit of neutrophils, taking into
account both the severity and the duration of neutropenia.
A spread sheet is used to calculate the area over the neu-
trophil curve, plotting the results of the ANC over the course
of neutropenia. At each new ANC value, a cumulative D-index
is calculated. The tool was retrospectively evaluated in a small
group of patients with IMD,  and for a cut-off value of 5800 the
NPV was very high.11
In the present study we selected a population of patients
at high risk for IMD: acute leukemia or MDS  undergoing
induction remission chemotherapy. Indeed, nine episodes
of proven or probable IMD  (31%) and one of possible IMD
were diagnosed. Caspofungin was chosen as the antifun-
gal agent in patients with suspicion of IMD because of its
indication and large use as empiric therapy in neutropenic
patients,23 and because of its favorable safety proﬁle. Con-
sidering that antifungal therapy was given in 12 episodes,
only two patients received antifungal therapy unnecessar-
ily. In addition, the application of the algorithm allowed us
to start antifungal therapy earlier than would be expected
if the empiric approach had been used: by day 7 of empiric
antibiotic therapy ﬁve patients were already on antifungal
therapy. 1 6;2  0(4):354–359
A cornerstone of the diagnostic driven approach is s-GMI.
Two different strategies have been evaluated in different stud-
ies. In one strategy serial s-GMI testing is performed during the
whole period at risk.6 In the other strategy, s-GMI is obtained
daily when patients are at high risk for IMD and present persis-
tent or recurrent fever or any sign suggestive of an IMD.22 The
two strategies have advantages and disadvantages. A poten-
tial disadvantage of the ﬁrst strategy is false positive s-GMI. In
addition to the potential interference of the test by the use of
anti-mold antifungal agents,24 the pre-test probability of IMD
is an important parameter in evaluating the PPV of the test;
the higher the pre-test probability of the disease the higher
is the PPV.25 Since the risk of invasive aspergillosis is a time
function of the duration of neutropenia,26 the D-index can
be of help in the interpretation of the performance of serum
biomarkers. With a dynamic risk stratiﬁcation based on the
intensity and duration of neutropenia, we  can estimate the
pre-test probability of IMD looking at the risk group. Indeed,
none of the patients considered as low risk at the time of
workup for IMD who had positive s-GMI had a diagnosis of
IMD. These data suggest that we can use the D-index risk strat-
iﬁcation to estimate the pre-test and post-test probability of
s-GMI.
The performance of the risk stratiﬁcation based on the D-
index can be appreciated by looking at the incidence of IMD in
the three risk categories. Furthermore, this strategy resulted
in a potential comprehensive use of antifungals if we  compare
with the classical empiric antifungal strategy, and antifungal
therapy was started in two afebrile patients, both with IMD.
Finally, the appropriate timing of initiation of antifungal ther-
apy may have been critical to the favorable outcome of patients
with IMD in this cohort.
Our study has an important limitation, the small sam-
ple size. Therefore, future studies with a larger number of
patients are needed. Nevertheless, the results of our study
may have important clinical implications. Our data suggest
that the incorporation of the D-index in an algorithm of
diagnostic-driven antifungal therapy may improve the per-
formance of fungal biomarkers, including s-GMI. With this
regard, and considering that patients in the low-risk group
undertaking workup for IMD are very likely to have false neg-
ative s-GMI, clinicians may wait for more  data (e.g. other
positive s-GMI) in order to trigger additional tests or to ini-
tiate antifungal therapy. Alternatively, clinicians may start
monitoring with s-GMI only once the cumulative D-index is
above 3000. By contrast, given the higher proportion of true
positive s-GMI in patients classiﬁed as intermediate or high
risk by D-index, additional workup and/or prompt initiation
of antifungal therapy may be a better option if s-GMI test is
positive.
Conclusions
In conclusion, the risk stratiﬁcation using the D-index was
a useful tool to a more  comprehensive antifungal strategy,
resulting in reduction of empirical therapy in low risk patients,
and guiding an earlier start of antifungal agents in afebrile
patients at high risk who presented an indirect sign of IMD.
Future studies with larger sample size are needed.
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